Enzymes, a powerful tool in the hands of chemists and a potential bridge between chemistry and biology

As active pharmaceutical ingredients become more complex, the cost of preparation increases exponentially when using classic chemical methodologies. In this regard, biocatalysis is becoming more and more interesting alternative as its enable atoms economy (through asymmetric synthesis for example) while reducing the overall process production (avoiding ‘protection-deprotection steps for example) in more environmental friendly conditions.

In order to provide all the benefits of biocatalysis to its customers, PCAS has formed PCAS Biosolution, a Joint-Venture with Proteus.

PCAS Biosolution is dedicated to developing and implementing new chemo-biocatalytic synthetic routes to active pharmaceutical ingredients, synthetic intermediates and key "building blocks".

This biocatalysis dedicated platform is fully integrated within the toolbox of PCAS synthetic chemistry to address chemo-, regio- and stereo-selectivity challenges.

You have access to: esterases, nitrilases, nitrile hydratases, amidases, epoxyde hydrolases, oxydo-reductases ...etc

Since 10 years, Proteus is a worldwide recognized biotechnology company which focuses on the discovery, engineering and proteins manufacturing for industrial interest, and on the development of innovative protein-based bioprocesses. The efficiency of Proteus' technology platform has been demonstrated by the successful track record of the company in the life science industry, including fine chemicals (pharmaceuticals), specialty chemicals (cosmetics, flavour and fragrances), healthcare, environment and bio-energy.